Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy

Abstract

Objective:revealing the role of morphophenotypic indices in the development of visceral obesity in patients with schizophrenia receiving quetiapine and risperidone therapy.Materials and methods.56 indoor patients with schizophrenia who received quetiapine (n= 23) or risperidone (n= 33) at medium doses were examined. Included persons were from 18 to 65 years old with at least a 1 year history of disease, the condition of which met the criteria of schizophrenia according to ICD-10. The Basis map of sociodemographic and clinical-dynamic signs for patients with schizophrenia was filled in, PANSS in the adapted Russian version – SCI-PANSS, noninvasive bioimpedancemetry, measurement of growth, transversethoracic, biacromial and bicrystal diameter, with calculation of body mass indexes, Tanner and Rees – Eysenk and definition of integral morphophenotypic indicators were carried out. Statistical processing was performed using Student’s t-test with a preliminary estimate of Pearson’s χ2 normal distribution, the Mann – Whitney U test to compare independent samples, the Spearman correlation analysis, the two-sided Fisher test.Results.There were no significant differences in both subgroups in terms of bioimpedancemetry. The correlation between the level of visceral fat and the Rees – Eysenk index in patients receiving risperidone was a moderate inverse: the greater the value of the Rees – Eysenk index, the lower the level of visceral fat (r= –0.73381,t= –4.70833,p= 0.00015). The correlation between the Tanner index and the level of visceral fat in the quetiapine subgroup was strong: the larger the Tanner index, the higher the visceral fat level (r= 0.7763,t= 4.08481,p= 0.00181); in the risperidone subgroup, there was an average direct correlation (r= 0.48133,t= 2.39356,p= 0.02716).Conclusion.The magnitude of the Rees – Eysenk index of schizophrenic patients can be considered among other factors in the management of risperidone in individuals with asthenic physique. The determination of the Tanner index at the beginning of treatment can play the role of a prognostic factor in the development of visceral obesity in patients with schizophrenia in the planned use as a basic therapy for quetiapine.

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals

“…This fits into the differences in approaches to antipsychotic therapy between hospitals discussed above and the general pattern of the formation of MetS, revealed in many studies, in particular, a large systematic review found that in patients with severe mental illness, a higher BMI was associated with lower levels of physical activity as a consequence of the lack of resources or professional support (44). Our previous study also showed the role of the bone component of body composition in the formation of MetS (45).…”

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome

“…It is important to control abdominal (including visceral) obesity, dyslipidemia, and increased glucose as components of the MetS already at the beginning of antipsychotic therapy. Visceral obesity occurs in 40-60% of schizophrenia patients and the accumulation of large amounts of abdominal and pericardial fat has considerable endocrine and cardiovascular consequences and negatively influences the health in general as well [18][19][20][21].…”

Модель Прогнозирования Метаболического Синдрома У Больных Параноидной Шизофренией

“…Согласно данным метаанализа, включающего более 25 000 пациентов с шизофренией, распространенность МС составила 32,5% [10]. Рассматривается возможность использования индекса Таннера (Tanner) в качестве прогностического фактора развития висцерального ожирения у больных шизофренией, получающих кветиапин [11].…”